Filter Results
:
(69)
Show Results For
-
All HBS Web
(111)
- News (22)
- Research (69)
- Events (1)
- Multimedia (3)
- Faculty Publications (48)
Show Results For
-
All HBS Web
(111)
- News (22)
- Research (69)
- Events (1)
- Multimedia (3)
- Faculty Publications (48)
←
Page 4 of
69
Results
Sort by
- 31 Jul 2012
- First Look
First Look: July 31
Confidential Instructions for Johnson & Johnson Guhan Subramanian and Rhea GhoshHarvard Business School Exercise 911-045 This two-party negotiation exercise features a real-life dispute between Merck and Johnson & Johnson...
View Details
Keywords:
Carmen Nobel
- 18 Apr 2017
- First Look
First Look at New Ideas, April 18
M&A) and Werner Baumann (CFO) have to decide whether to increase the cash portion of their $14.2 billion offer and/or amend the terms of a proposed joint venture (JV) with Merck involving cardiovascular drugs that had been included in...
View Details
Keywords:
by Sean Silverthorne
- 30 May 2007
- Research & Ideas
Health Care Under a Research Microscope
including Bohmer, a physician; Bill George, former chairman and CEO of Medtronic; Raymond Gilmartin, former chairman, president, and CEO of Merck & Co.; Robert Huckman, a former health care consultant and now Faculty Research Fellow...
View Details
- 02 Oct 2000
- Research & Ideas
The Dubious Logic of Global Megamergers
moves itself. According to industry observers, Merck intends to use this period in which its competitors are busy with postmerger integration to improve its position through aggressive marketing and other initiatives. Make Friends....
View Details
Keywords:
by Pankaj Ghemawat & Fariborz Ghadar
- 01 May 2007
- First Look
First Look: May 1, 2007
http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=207113 Strategy in the 21st Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc. Harvard Business School Case 707-509 The global pharmaceutical industry has gone...
View Details
Keywords:
Sean Silverthorne
- 17 Jul 2012
- First Look
First Look: July 17
Science-Based Business (Abridged) Ananth Raman and Inga MaurerHarvard Business School Case 611-027 Ray Gilmartin faces a dilemma. His company's credibility has been damaged by the recent withdrawal of Vioxx, a multi-billion dollar drug. Moreover, the withdrawal of...
View Details
Keywords:
Sean Silverthorne